Infant Bacterial Therapeutics Investor Relations Material
Latest events
Study Update
Infant Bacterial Therapeutics
Q1 2025
7 May, 2025
Q4 2024
13 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Infant Bacterial Therapeutics
Access all reports
Infant Bacterial Therapeutics is a Sweden-based pharmaceutical company focused on developing microbiome-based treatments for diseases affecting premature infants and children. Its primary focus is on preventing necrotizing enterocolitis and other serious conditions using live bacterial therapies. Infant Bacterial Therapeutics is headquartered in Stockholm, Sweden, and its shares are listed on the NASDAQ Stockholm.
Latest articles
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
)
Costco Wholesale: The Model of Scalable Simplicity
Costco's rise from warehouse club to retail giant is built on low prices, scale efficiency, and a model designed for lasting customer value.
26 May 2025
Ticker symbol
IBT
Country
🇸🇪 Sweden